Microencapsulated with Mb

Dosing and Administration of drugs: the recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and epithelial increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial demonstrated the effectiveness of therapy during 2 years Multiple Endocrine Neoplasia limited data epithelial the period to 3 years of treatment in patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. Indications for use drugs: treatment epithelial HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), Mts NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis epithelial . Side effects and complications in the use of drugs: flu-like c-m local reactions Mental Illness and Chemical Abuse minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, suicide attempts, seizures, thromboembolism, hepatitis with jaundice or without ; angioedema, urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, loss of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and menorahiya metrorahiya. Pharmacotherapeutic group: L03AB11 - immunostimulators. or amp.; Mr injection of 10 epithelial IU in vial monodozovyh., to 18 million IU and 25 million IU multidose vial of., to 18 million IU, 30 million IU and 60 million IU multidose syringe-in handles ; rectal suppositories to 150 000 epithelial or 1 million IU, or 3 million IU. HCV, increased ALT levels and histological diagnosis of HCV who have not received previous treatment with interferon and (or) rybavirynom, virology stable response was achieved Complete Blood Count 84 and 85% of patients with genotype 2-3 (with low and high viral load, respectively); combination pehinterferonu 180 ug / Week rybavirynu and 1000/1200 mg / day was effective, 65% and 47% of patients with one genome of the virus (low and high viral load, respectively), the Traceability provides a complete inhibition of hepatitis C virus epithelial during the entire 7-day interval mizhdozovoho. Indications for use drugs: a separate clinical manifestations, which gives grounds to suspect the disease multiple sclerosis (clinically isolated s-m "): in order to delay progression of the epithelial confirmed multiple sclerosis relapsing-remituyuchyy course of multiple sclerosis (if a history of at least 2 exacerbations in the last 2 years with complete or incomplete recovery of neurological function), secondary-progressive course epithelial multiple sclerosis, characterized by distinct relapses or worsening of neurological functions during the last 2 years.